Online Program Home
My Program

Abstract Details

Activity Number: 700
Type: Contributed
Date/Time: Thursday, August 4, 2016 : 10:30 AM to 12:20 PM
Sponsor: Biometrics Section
Abstract #319092 View Presentation
Title: Sample Size Methods for Validating Treatment Selection Cancer Biomarkers from Right-Censored Survival Data
Author(s): Kevin Dobbin* and Lisa M. McShane
Companies: University of Georgia and National Cancer Institute
Keywords: Sample Size ; Biomarker ; Treatment Selection ; Cancer

Treatment selection biomarkers are used to identify patients who will benefit from a specific therapy. Typically, treatment selection biomarkers are used to refine treatment protocols, so that treatment is determined by the measured biomarker values. An imperfect example is OncoTypeDX, which is used to refine treatment for node negative, hormone receptor positive breast cancer patients treated with endocrine therapy, dividing them into a group that receives adjuvant chemotherapy and a group that does not. This is called ``marker-guided therapy." This and other examples will be discussed. We present novel sample size methods for inference about the change in the the population proportion of patients who survive a specified time (e.g., 5 years) if all receive marker-guided therapy, a metric previously developed by others. The methods are appropriate for studies that produce right-censored survival data.

Authors who are presenting talks have a * after their name.

Back to the full JSM 2016 program

Copyright © American Statistical Association